HealthCare Global Enterprises (HCG), India's leading oncology-focused hospital network, has announced ambitious plans to expand its capacity by 1,000 new beds and significantly grow its diagnostics footprint over the next five years. The company projects a capital expenditure of approximately ₹600 crore to fuel this expansion, targeting both greenfield projects and brownfield enhancements.
Strategic Expansion and Funding
Dr. Manish Mattoo, CEO and Executive Director of HCG, detailed the expansion strategy, highlighting that roughly 40% of the new beds will come from greenfield projects, with the remaining 500-600 beds added through brownfield expansion. Greenfield projects, which involve establishing entirely new facilities, typically cost around ₹1 crore per bed, while brownfield expansions, which involve adding capacity to existing hospitals, are more capital-efficient at ₹30-35 lakh per bed.
The company currently operates 25 hospitals across 19 cities and is actively evaluating acquisition opportunities in 10-12 new cities, including Pune, Coimbatore, Hyderabad, Chennai, Delhi, and Lucknow. Existing centers in Bengaluru, Mumbai, and Ahmedabad are also undergoing expansion to solidify HCG's market-leading positions and establish regional hubs to support growth in surrounding areas like Pune, Aurangabad, Nashik, and Nagpur from Mumbai, and broader eastern and western India from Kolkata and Ahmedabad, respectively.
Addressing India's Growing Cancer Burden
India recorded an estimated 1.56 million new cancer cases in 2024, according to the International Agency for Research on Cancer (IARC)'s GLOBOCAN estimates. HCG consults around 500,000 patients and treats approximately 100,000 new patients annually, underscoring the vast, underserved demand for specialized oncology care, particularly outside major metropolitan areas.
To complement its hospital network, HCG plans to expand its diagnostic centers from the current 20 to 40 over the next three to four years. This move is crucial for improving patient acquisition and facilitating earlier diagnosis, which is critical for effective cancer treatment outcomes.
Competitive Edge and Technological Advancements
HCG maintains its competitive advantage through over 35 years of specialized focus on cancer care, building deep expertise across medical oncology, surgical oncology, precision oncology, and bone marrow transplantation. This is supported by a robust protocol-driven and research-led model.
The company has invested significantly in advanced medical technology, including PET-CT, CyberKnife, LINACs, surgical robotics, and comprehensive genomics. Through advanced genomic profiling and next-generation sequencing, HCG enables oncologists to tailor personalized treatment decisions based on a deeper understanding of tumor biology. Furthermore, digital pathology, teleradiology, and telemedicine are leveraged to extend these capabilities across its extensive network. HCG is also bringing an MR LINAC, a state-of-the-art radiation therapy system, to North Bengaluru, marking a first for Karnataka.
Profitability and Future Outlook
While HCG has seen revenue growth of 15% and EBITDA growth of 22% year-on-year, operating leverage has been impacted by investments in digital capabilities, clinical talent, and sales and marketing. However, with most of these investments now complete, the company anticipates stronger operating leverage as utilization improves and the payor mix normalizes. Mature centers typically achieve EBITDA margins of about 25% and a return on capital employed above 20%.
HCG also collaborates with government initiatives like Ayushman Bharat and various cancer screening partnerships, recognizing their importance in improving access and early detection, despite challenges related to reimbursement rates and payment delays. The biggest opportunity for HCG remains in expanding access to quality specialized cancer care across India, given the country's growing cancer burden and underserved healthcare infrastructure.